A phase III, double-blind, randomized, placebo-controlled study of JBT-101 in diffuse cutaneous systemic sclerosis

Trial Profile

A phase III, double-blind, randomized, placebo-controlled study of JBT-101 in diffuse cutaneous systemic sclerosis

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 According to a Corbus Pharmaceuticals media release, the company expects to report topline results before the end of 2019.
    • 23 Oct 2017 According to a Corbus Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
    • 09 Aug 2017 Planned number of patients changed from 270 to 350 according to a Corbus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top